跳至主導覽 跳至搜尋 跳過主要內容

Potential therapeutic targets beyond cytokines and Janus kinases for autoimmune arthritis

  • Chao Yi Wu
  • , Huang Yu Yang
  • , Jenn Haung Lai*
  • *此作品的通信作者
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Defense Medical University

研究成果: 期刊稿件 › 文獻綜述 › 同儕審查

7 引文 斯高帕斯(Scopus)

摘要

Synovial inflammation and destruction of articular cartilage and bone are hallmarks of autoimmune arthritis. Although current efforts to inhibit proinflammatory cytokines (biologics) or block Janus kinases (JAK) appear to be promising in many patients with autoimmune arthritis, adequate disease control is still lacking in a significant proportion of autoimmune arthritis patients. The possible adverse events from taking biologics and JAK inhibitors, such as infection, remain a major concern. Recent advances showing the effects of a loss of balance between regulatory T cells and T helper-17 cells as well as how the imbalance between osteoblastic and osteoclastic activities of bone cells exaggerates joint inflammation, bony destruction and systemic osteoporosis highlight an interesting area to explore in the search for better therapeutics. The recognition of the heterogenicity of synovial fibroblasts in osteoclastogenesis and their crosstalk with immune and bone cells provides an opportunity for identifying novel therapeutic targets for autoimmune arthritis. In this commentary, we comprehensively review the current knowledge regarding the interactions among heterogenic synovial fibroblasts, bone cells and immune cells and how they contribute to the immunopathogenesis of autoimmune arthritis, as well as the search for novel therapeutic targets not targeted by current biologics and JAK inhibitors.

原文英語
文章編號115622
頁(從 - 到)115622
期刊Biochemical Pharmacology
卷213
DOIs
出版品狀態已出版 - 07 2023

文獻附註

Copyright © 2023. Published by Elsevier Inc.

指紋

深入研究「Potential therapeutic targets beyond cytokines and Janus kinases for autoimmune arthritis」主題。共同形成了獨特的指紋。

引用此